Long-Term Efficacy and Safety of Everolimus-Eluting Stent Implantation in Japanese Patients with Acute Coronary Syndrome: Five-Year Real-World Data from the Tokyo-MD PCI Study
المؤلفون المشاركون
Yoshikawa, Shunji
Ashikaga, Takashi
Miyazaki, Toru
Kurihara, Ken
Hirao, Kenzo
المصدر
Journal of Interventional Cardiology
العدد
المجلد 2019، العدد 2019 (31 ديسمبر/كانون الأول 2019)، ص ص. 1-13، 13ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2019-11-03
دولة النشر
مصر
عدد الصفحات
13
التخصصات الرئيسية
الملخص EN
Background.
The long-term safety of first-generation drug-eluting stent (DES) in acute coronary syndrome (ACS) was controversial.
Purpose.
The purpose of this study was to establish 5-year real-world data regarding the long-term efficacy and safety of second-generation DES in Japanese patients with ACS.
Methods.
The Tokyo-MD PCI study is a multicenter, observational cohort study enrolling consecutive patients who underwent everolimus-eluting stent (EES) implantation.
The 5-year clinical events were compared between the ACS group (n = 644) and the stable coronary artery disease (SCAD) group (n = 1255).
The primary efficacy endpoint was ischemia-driven target lesion revascularization (TLR), and the primary safety endpoint was the composite of all-cause death or myocardial infarction (MI).
Results.
The median follow-up duration was 5.4 years.
The cumulative incidence of ischemia-driven TLR was similar between ACS and SCAD (1 year: 3.0% versus 2.7%; P=0.682, 1–5 years: 2.7% versus 2.9%; P=0.864).
The cumulative incidence of all-cause death or MI within 1 year was significantly higher in ACS than in SCAD (7.4% versus 3.8%; P<0.001); however, ACS did not increase the risk of all-cause death or MI after adjusting confounders (adjusted hazard ratio, 1.260; 95% confidence interval, 0.774–2.053; P=0.352).
From 1 to 5 years, the cumulative incidence of all-cause death or MI was not significantly different between ACS and SCAD (11.6% versus 11.4%; P=0.706).
The cumulative incidence of very late stent thrombosis was low and similar between ACS and SCAD (0.2% versus 0.2%; P=0.942).
Conclusion.
This real-world registry suggested that EES has comparable long-term efficacy and safety in patients with ACS and SCAD.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Yoshikawa, Shunji& Ashikaga, Takashi& Miyazaki, Toru& Kurihara, Ken& Hirao, Kenzo. 2019. Long-Term Efficacy and Safety of Everolimus-Eluting Stent Implantation in Japanese Patients with Acute Coronary Syndrome: Five-Year Real-World Data from the Tokyo-MD PCI Study. Journal of Interventional Cardiology،Vol. 2019, no. 2019, pp.1-13.
https://search.emarefa.net/detail/BIM-1181209
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Yoshikawa, Shunji…[et al.]. Long-Term Efficacy and Safety of Everolimus-Eluting Stent Implantation in Japanese Patients with Acute Coronary Syndrome: Five-Year Real-World Data from the Tokyo-MD PCI Study. Journal of Interventional Cardiology No. 2019 (2019), pp.1-13.
https://search.emarefa.net/detail/BIM-1181209
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Yoshikawa, Shunji& Ashikaga, Takashi& Miyazaki, Toru& Kurihara, Ken& Hirao, Kenzo. Long-Term Efficacy and Safety of Everolimus-Eluting Stent Implantation in Japanese Patients with Acute Coronary Syndrome: Five-Year Real-World Data from the Tokyo-MD PCI Study. Journal of Interventional Cardiology. 2019. Vol. 2019, no. 2019, pp.1-13.
https://search.emarefa.net/detail/BIM-1181209
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1181209
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر